Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Type 2 Diabetes Market Revenue Growth Supported By A CAGR Of 78.66% Through 2030
The market for type 2 diabetes treatments has experienced robust expansion. Projections indicate a rise from $51.47 billion in 2025 to $55.53 billion by 2026, reflecting a compound annual growth rate of 7.9%. Key factors contributing to the market’s historical surge include the escalating worldwide incidence of obesity, a rise in physically inactive lifestyles, broader accessibility to oral antidiabetic medications, enhanced detection of metabolic conditions, and improvements in accessing foundational diabetes care.
The market for type 2 diabetes treatments is poised for significant expansion, with projections indicating a substantial increase to $78.67 billion by the year 2030, reflecting a compound annual growth rate of 9.1%. This anticipated surge is fueled by several key factors, including a heightened demand for therapeutic options that prioritize weight management, a growing tendency towards individualized diabetes care strategies, the broadening reach of digital health solutions, an intensified focus on preventing the onset of diabetes, and increased investment in the development of innovative antidiabetic medications. Furthermore, prevailing trends expected to shape this market during the forecast period encompass a greater utilization of GLP-1 receptor agonists, an elevated emphasis on managing cardiometabolic risks concurrently, a rise in the application of combination therapies, the wider integration of lifestyle-based treatment modalities, and a stronger commitment to achieving sustained glycemic control over the long term.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp
Type 2 Diabetes Market Opportunity Drivers: What Is Creating New Revenue Potential?
The escalating prevalence of obesity and cardiovascular ailments is anticipated to be a significant catalyst for the expansion of the type 2 diabetes market. Obesity, characterized by an unhealthy accumulation of body fat, and heart disease, encompassing various conditions affecting the heart and its vasculature, are closely linked to the rise of type 2 diabetes. Excessive weight gain heightens the likelihood of insulin resistance, resulting in elevated blood glucose levels and the subsequent onset of type 2 diabetes. Conversely, persistently high blood sugar can inflict damage upon the blood vessels and the neural pathways governing cardiovascular function, thereby contributing to heart disease. As an illustration, a report issued in March 2024 by the World Health Organization (WHO), an international body headquartered in Switzerland, indicated that nearly 12.5% of the global population faces the challenge of obesity, with 2.5 billion adults (18 and above) being overweight, and 890 million of these individuals classified as obese. Within the adult demographic, 43% were identified as overweight, and 16% met the criteria for obesity. Furthermore, the figure for overweight children under five years of age stood at 37 million. Consequently, the increasing incidence of obesity and heart disease is a direct driver behind the growth observed in the type 2 diabetes market.
Type 2 Diabetes Market Segments: Where Are The Largest Growth Opportunities?
The type 2 diabetes market covered in this report is segmented –
1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes
2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications
3) By End-User: Children, Adults
Subsegments:
1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide
6) By Biguanides: Metformin, Buformin, Phenformin
7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists
Type 2 Diabetes Market Innovation Trends Driving Future Development
Leading pharmaceutical firms in the type 2 diabetes sector are prioritizing the creation of innovative treatments, specifically dual-action SGLT2/GLP-1 therapies with expanded uses, aiming to achieve superior blood sugar management, mitigate associated health complications, and boost patient compliance. These combined SGLT2 inhibitor and GLP-1 receptor agonist therapies, also available as fixed-dose preparations, are designed to concurrently address glucose regulation, weight management, and cardiovascular and kidney health in individuals diagnosed with type 2 diabetes. A notable development occurred in June 2024 when AstraZeneca, a biopharmaceutical giant, secured U.S. FDA authorization for Farxiga (dapagliflozin) to treat type 2 diabetes in pediatric patients aged 10 and above, signifying a strategic move to encompass a wider demographic beyond adults. This advancement provides a convenient once-daily oral option for younger individuals, incorporates comprehensive data on cardioprotective and renoprotective benefits, and facilitates market penetration into pediatric and nascent stages of type 2 diabetes, thereby propelling the expansion of the worldwide type 2 diabetes market.
Type 2 Diabetes Market Major Participants And Competitive Dynamics
Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health
Access The Complete Type 2 Diabetes Market Report:
https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report
Type 2 Diabetes Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the type 2 diabetes market in 2025. Europeis expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model